【个人简介】

杨子峰，博士，研究员，现任广州医科大学附属第一医院广州呼吸健康研究院副院长、呼吸疾病全国重点实验室副主任、中国-葡萄牙人工智能与公共卫生问题“一带一路”联合实验室副主任。国家级高层次人才、国务院特殊津贴专家。

在紧扣临床需求的呼吸系统传染病、重大呼吸慢病的动物模型构建及重大呼吸系统传染病及慢病的创新药物研发领域有丰富的研究经验及成果。已在Science、New England、Lancet和Nature子刊等国际高水平期刊发表200多篇文章。授权国家发明专利20余项。主持十多项国家自然科学基金面上和专项项目、国家重点研发计划、科技部港澳台科技合作专项及省市级课题。

【研究方向】

中西医结合防治呼吸感染的诊断与治疗

【科研项目】

1.国家科技重大专项项目-基于卫气营血理论的中药复方治疗重症肺炎清热与化瘀免疫调节机制与物质基础研究，2025.2-2029.1，800万，在研，主持

2.国家中医药管理局项目-中西医结合防治重大突发呼吸系统疾病研究多学科交叉创新团队，2025.8-2028.7，500万，在研，主持

3.国家自然科学基金联合基金项目，融合因果推理的重症肺炎呼吸衰竭异质性机制解析与精准决策系统研发，2026.1-2029.12，206万，在研，主持

4.国家自然科学基金专项项目，临床价值导向的新冠病毒3CLpro单药口服抑制剂的长效机制研究及研发，2024-1-1至2026-12-31，200万，在研，主持

5.国家自然科学基金国际(地区)合作与交流项目，基于自适应Fourier分解模型的人季节性流感病毒血 凝素蛋白抗原进化精准预测研究，2024-1-1至2026-12-31，160万，在研，主持

6.国家重点研发计划，冬奥会相关人群新冠疫情传播风险链分析技术，2021.4-1至2022-6-30，82万，已结题，主持

7.国家自然科学基金面上项目，基于中药单体连翘苷抗新冠活性发现靶向病毒生命周期蛋白及其免疫炎症调控机制研究，2022.1-1至2025-12-31，56万，已结题，主持

【代表性论文及著作】

1.Yang ZF^#,Mok CKP^# ,Peiris JSM, Zhong NS^*.Human Infection with a Novel Avian Influenza A(H5N6) Virus , N Engl J Med , 2015, 373(5): 487~489

2.Yang ZF^#,Leung ELH^#,Liu L,Jiang ZH,Zhong NS^*.Developing influenza treatments using traditional Chinese medicine , Science, 2015, 347(6219 Suppl): S35~S37

3.Zifeng Yang#, Zhengtu Li#, Yangqing Zhan#, Zhengshi Lin#, Zhonghao Fang#, Xiaowei Xu#, Lin Lin#, Haijun Li#,  Zejun Lin, Changyuan Kang, Jingyi Liang, Shiwei Liang, Yongming Li, Shaoqiang Li, Xinyun Yang, Feng Ye, Nanshan Zhong*.Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection: a multi-center, double-blind, randomized, placebo-controlled phase 2 trial,lancet infectious diseases,2024,24(5):535-545

4.Xiaoxin Chen #, Xiaodong Huang #, Qinhai Ma #, Petr Kuzmič #, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jinsong Liu, Tianyu Zhang, James Spencer, Zhenzhen Zhu, Wenbin Deng, Xinwen Chen, Shu-Hui Chen, Nanshan Zhong*, Xiaoli Xiong*, Zifeng Yang*.Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 with improved pharmacokinetics compared to nirmatrelvir.nature microbiology,2024,9(4):1075-1088

5.Zifeng Yang*, Yangqing Zhan*, Zhengtu Li*, Zhengshi Lin*, Zhonghao Fang*, Haijun Li*, Xiaolin Chen*, Banghan Ding*, Huiqing Zeng*, Xiuwei Zhang*, Yudi Song, Zejun Lin, Shiwei Liang, Jincan Luo, Jufang Huang, Xiaoxin Chen#, Nanshan Zhong#.Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial ,Lancet Respir Med,2025,13(7):597-610

6.Wenda Guan#, Rong Qu#, Lihan Shen#, Kailin Mai#, Weiqi Pan#, Zhengshi Lin#, Liping Chen, Ji Dong , Jiawei Zhang , Pei Feng , Yunceng Weng , Minfei Yu, Peikun Guan, Jinchao Zhou, Chuanmeizi Tu, Xiao Wu, Yang Wang, Chunguang Yang , Yun Ling , Sheng Le , Yangqing Zhan, Yimin Li , Xiaoqing Liu, Heyan Zou, Ziqi Huang , Hongxia Zhou, Qiubao Wu, Wenjie Zhang, Jiayang He, Teng Xu, Nanshan Zhong*, Zifeng Yang*.Baloxavir marboxil use for critical human infection of avian influenza A H5N6 virus.MED,2024,S2666-6340(23)00361-6.

7.Jingyi Liang^#, Zhufeng Wang^#, Yong Liu^#, Linxiu Zeng, Zhengtu Li, Jiamin Liang, Hanwen Liang , Mei Jiang*, Zifeng Yang*. Epidemiology and co-infection patterns in patients with respiratory tract infections in southern China between 2018 and 2020, J Infect,2021, 83(3):e6-e8

8.Chen Hua^#, Qinhai Ma^#, Yun Zhu^#, Shuai Xia, Zezhong Liu, Lin Li, Lu Lu,Nanshan Zhong,Shuwen Liu*,Zifeng Yang*,Shibo Jiang*.Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation, Signal Transduct Target Ther.2021; 6(1):318.

9.Yangqing Zhan#, Zhengshi Lin#, Jingyi Liang#, Ruilin Sun#, Yueping Li#, Bingliang Lin#, Fangqi Ge#, Ling Lin#, Hongzhou Lu#, Liang Su, Tianxin Xiang, Hongqiu Pan, Chaolin Huang , Ying Deng , Furong Wang , Ruhong Xu, Dexiong Chen, Ping Zhang, Jianlin Tong, Xifu Wang, Qingwei Meng, Zhigang Zheng, Shuqiang Ou, Xiaoyun Guo, Herui Yao, Tao Yu , Weiyang Li, Yu Zhang, Mei Jiang, Zhonghao Fang, Yudi Song , Ruifeng Chen, Jincan Luo, Changyuan Kang, Shiwei Liang, Haijun Li; other Collaborative Institutes; Jingping Zheng*, Nanshan Zhong*, Zifeng Yang*.Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.EClinicalMedicine,2023,67:102359

10.Qinhai Ma#, peifang Xie #, Yangqing Zhan #, Ruihan chen#, Bin Liu#, Yongjie su,Wanli Qiu, Xuanxuan Li, Tingting Zhao, Nanshan Zhong*, Zifeng Yang*.Elucidating Forsythin’s Anti-Inflammatory Action Through Modulation of the P38 MAPK Pathway in SARS-CoV-2 Infection.Engineering,2025,187–201

【所获荣誉和奖励】

1.2021年荣获国家科技进步奖创新团队奖

2.2019年荣获广东省科技进步一等奖

3.2020年荣获广东省科技进步特等奖

4.2020年荣获全国创新争先奖牌

5.2025年荣获中国药学发展奖·突出成就奖

6.2023年荣获广东省丁颖科技奖

7.2026年荣获中华中医药学会科技进步一等奖

8.2021年荣获国家级高层次人才称号

9.2023年荣获国务院特殊津贴专家

10.2025年荣获广东省特支计划杰出人才